<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02011464</url>
  </required_header>
  <id_info>
    <org_study_id>2013-11-02</org_study_id>
    <nct_id>NCT02011464</nct_id>
  </id_info>
  <brief_title>Evaluation Exparel Delivered in Knee Replacement</brief_title>
  <official_title>Evaluation of the Efficacy of Exparel Delivered Into the Posterior Capsule During Knee Replacement</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maimonides Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maimonides Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pain control after knee replacement requires analgesia to both the top (anterior) and bottom
      (posterior) portion of the the knee. Presently we use a nerve block for the anterior portion.
      The investigators want to to examine if giving Exparel into the posterior portion will give
      better pain relief.

      Hypothesis: There is no difference in, the use of analgesics or the length and quality of
      analgesia and no decrease in the time to be able to accomplish simple to complex knee
      movements using Exparel infiltration when compared to controls.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives:

        1. Is to assess the efficacy of pain control of Exparel vs. controls when injected into the
           posterior capsular space after total knee arthroplasty

        2. Asses the opioid use after Exparel vs. controls

        3. Asses the time to simple and complex knee movement and ambulation.

        4. The safety of Exparel will be assessed by the occurrence of all postsurgical adverse
           events and serious adverse events through Day 30.

      Methods:

      After institutional review board (IRB) approval, 20 subjects will be consented to participate
      in the study. The study includes subjects undergoing total knee arthroplasty either under
      general or spinal anesthesia. This study will include men and women (18 - 75 years) who have
      American Society of Anesthesiologist physical classification status 1 - 3 and underwent total
      knee arthroplasty.

      Subjects will be divided into two groups, Group A (control) to receive 20ml of saline while
      Group B (study) to receive 20ml of liposomal bupivacaine into the posterior capsular space
      during total knee arthroplasty. Patients from both groups will receive a femoral nerve block
      with catheter placement for continuous infusion of local anesthetic. All subjects will have
      access to rescue analgesics after surgery. Multimodal analgesia will supplement pain as per
      standard care by the anesthesia team. Tylenol Orally 1g three times daily (not to exceed 4g
      in 24hrs), oxycontin 10mg orally, twice/day, Celebrex 200 mg orally once a day and Percocet
      5/325 prn will serve as this multimodal approach. The time, day and number of requests for
      break through (additional) analgesia will be noted by both anesthesia team and primary care
      team. Pain scores will be assessed using a 0 - 10 numeric scale. Pain will be assessed for
      the following intervals: hospital arrival, post anesthesia care unit (PACU) arrival, 2, 4, 8,
      12, 24, 48, 72, hours later and after hospital discharge 10 +/- 5 days after the block. Pain
      inquiries will assess both posterior and anterior aspects of the knee. Pain at rest and for
      simple leg movements (knee extension, straight leg raise) to fully ambulatory will be noted.
      These assessments will be made in conjunction with rehabilitation and physical therapy
      specialists.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Subjective Pain</measure>
    <time_frame>72 hours post-operative</time_frame>
    <description>Subject reported post-surgical pain using the visual analog scale (VAS) during the hospital stay and after discharge. This is a 0-10 point numeric rating scale where 0 is no pain and 10 is the highest level of pain.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Post-operative Narcotic Use</measure>
    <time_frame>72 hours post-operative</time_frame>
    <description>Average postoperative narcotics administered in total milligrams of morphine equivalents</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Side Effects of Analgesia</measure>
    <time_frame>72 hours post-operative</time_frame>
    <description>Secondary end points will include the incidence of opioid related side effects (nausea, vomiting, pruritis, constipation, respiratory depression, and hypoxia) and hemodynamic perturbations related to pain</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Arthritis</condition>
  <arm_group>
    <arm_group_label>Exparel infiltration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Exparel infiltrated into the posterior compartment of the knee</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline infiltrated into posterior compartment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exparel</intervention_name>
    <description>Exparel is infiltrated into posterior compartment for pain control</description>
    <arm_group_label>Exparel infiltration</arm_group_label>
    <other_name>Bupivacaine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Saline is infiltrated into posterior compartment for control</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged 18-75 years inclusive and American Society of Anesthesiologist physical
             status 1-3

          -  Patients undergoing knee replacement (total knee arthroplasty)

          -  Subjects must be physically and mentally able to participate in the study and complete
             all study assessments.

          -  Subjects must be able to give fully informed consent to participate in this study
             after demonstrating a good understanding of the risks and benefits of the proposed
             components of infiltration into the posterior capsule of the knee.

        Exclusion Criteria:

          -  History of hypersensitivity or idiosyncratic reactions to amide-type local anesthetics

          -  Any subject whose anatomy, or surgical procedure, in the opinion of the Investigator,
             might preclude the potential successful performance of a appropriate Exparel
             infiltration into the posterior capsule of the knee.

          -  Any subject who in the opinion of the Investigator, might be harmed or be a poor
             candidate for participation in the study.

          -  Any subject, who in the opinion of the Investigator, is on chronic pain medicine
             (opioids), including large doses of non-steroidal anti-inflammatory drugs s.

          -  Subjects who have received any investigational drug within 30 days prior to study drug
             administration, or planned administration of another investigational product or
             procedure during their participation in this study.

          -  History of pre-existing neurological disorders/neuropathy

          -  Morbid Obesity
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Piyush Gupta, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maimonides Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maimonides Medical Center</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 10, 2013</study_first_submitted>
  <study_first_submitted_qc>December 12, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 13, 2013</study_first_posted>
  <results_first_submitted>June 6, 2016</results_first_submitted>
  <results_first_submitted_qc>July 7, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">August 8, 2017</results_first_posted>
  <last_update_submitted>July 7, 2017</last_update_submitted>
  <last_update_submitted_qc>July 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Exparel Inflitration</title>
          <description>Exparel infiltrated into the posterior compartment of the knee</description>
        </group>
        <group group_id="P2">
          <title>Control</title>
          <description>Saline infiltrated into posterior compartment of the knee</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Exparel Inflitration</title>
          <description>Exparel infiltrated into the posterior compartment of the knee</description>
        </group>
        <group group_id="B2">
          <title>Control</title>
          <description>Saline infiltrated into posterior compartment</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Males and females between the ages 18 and 75 years old</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.1" spread="4.7"/>
                    <measurement group_id="B2" value="62.8" spread="6.0"/>
                    <measurement group_id="B3" value="64.1" spread="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Subjective Pain</title>
        <description>Subject reported post-surgical pain using the visual analog scale (VAS) during the hospital stay and after discharge. This is a 0-10 point numeric rating scale where 0 is no pain and 10 is the highest level of pain.</description>
        <time_frame>72 hours post-operative</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Exparel Group/Average Pain Scores at 4 Hours</title>
            <description>Pain scores using the Number Rating Scale (NRS) from 0 - 10</description>
          </group>
          <group group_id="O2">
            <title>Control Group/Average Pain Scores at 4 Hours</title>
            <description>Pain scores using the Numeric Rating Scale (NRS) 0 - 10</description>
          </group>
          <group group_id="O3">
            <title>Exparel Group/Average Pain Scores at 8 Hours</title>
            <description>Pain scores using the Number Rating Scale (NRS) from 0 - 10</description>
          </group>
          <group group_id="O4">
            <title>Control Group/Average Pain Scores at 8 Hours</title>
            <description>Pain scores using the Number Rating Scale (NRS) from 0 - 10</description>
          </group>
          <group group_id="O5">
            <title>Exparel Group/Average Pain Scores at 12 Hours</title>
            <description>Pain scores using the Numeric Rating Scale (NRS) 0 - 10</description>
          </group>
          <group group_id="O6">
            <title>Control Group/Average Pain Scores at 12 Hours</title>
            <description>Pain scores using the Numeric Rating Scale (NRS) 0 - 10</description>
          </group>
          <group group_id="O7">
            <title>Exparel Group/Average Pain Scores at 24 Hours</title>
            <description>Pain scores using the Numeric Rating Scale (NRS) 0 - 10</description>
          </group>
          <group group_id="O8">
            <title>Control Group/Average Pain Scores at 24 Hours</title>
            <description>Pain scores using the Numeric Rating Scale (NRS) 0 - 10</description>
          </group>
          <group group_id="O9">
            <title>Exparel Group/Average Pain Scores at 48 Hours</title>
            <description>Pain scores using the Numeric Rating Scale (NRS) 0 - 10</description>
          </group>
          <group group_id="O10">
            <title>Control Group/Average Pain Scores at 48 Hours</title>
            <description>Pain scores using the Numeric Rating Scale (NRS) 0 - 10</description>
          </group>
          <group group_id="O11">
            <title>Exparel Group/Average Pain Scores at 72 Hours</title>
            <description>Pain scores using the Numeric Rating Scale (NRS) 0 - 10</description>
          </group>
          <group group_id="O12">
            <title>Control Group/Average Pain Scores at 72 Hours</title>
            <description>Pain scores using the Numeric Rating Scale (NRS) 0 - 10</description>
          </group>
        </group_list>
        <measure>
          <title>Subjective Pain</title>
          <description>Subject reported post-surgical pain using the visual analog scale (VAS) during the hospital stay and after discharge. This is a 0-10 point numeric rating scale where 0 is no pain and 10 is the highest level of pain.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="10"/>
                <count group_id="O7" value="10"/>
                <count group_id="O8" value="10"/>
                <count group_id="O9" value="10"/>
                <count group_id="O10" value="10"/>
                <count group_id="O11" value="10"/>
                <count group_id="O12" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.80" spread="3.26"/>
                    <measurement group_id="O2" value="4.00" spread="2.75"/>
                    <measurement group_id="O3" value="3.44" spread="3.61"/>
                    <measurement group_id="O4" value="5.30" spread="3.02"/>
                    <measurement group_id="O5" value="3.50" spread="3.25"/>
                    <measurement group_id="O6" value="3.90" spread="2.47"/>
                    <measurement group_id="O7" value="3.80" spread="3.52"/>
                    <measurement group_id="O8" value="4.20" spread="2.82"/>
                    <measurement group_id="O9" value="2.60" spread="2.46"/>
                    <measurement group_id="O10" value="3.50" spread="2.95"/>
                    <measurement group_id="O11" value="3.00" spread="3.16"/>
                    <measurement group_id="O12" value="3.70" spread="3.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-operative Narcotic Use</title>
        <description>Average postoperative narcotics administered in total milligrams of morphine equivalents</description>
        <time_frame>72 hours post-operative</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Exparel Inflitration</title>
            <description>Exparel infiltrated into the posterior compartment of the knee</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Saline infiltrated into posterior compartment</description>
          </group>
        </group_list>
        <measure>
          <title>Post-operative Narcotic Use</title>
          <description>Average postoperative narcotics administered in total milligrams of morphine equivalents</description>
          <units>mgs</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.31" spread="2.40"/>
                    <measurement group_id="O2" value="5.75" spread="3.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Side Effects of Analgesia</title>
        <description>Secondary end points will include the incidence of opioid related side effects (nausea, vomiting, pruritis, constipation, respiratory depression, and hypoxia) and hemodynamic perturbations related to pain</description>
        <time_frame>72 hours post-operative</time_frame>
        <population>Number of patients with opioid related side effects (nausea, vomiting, pruritis, constipation, respiratory depression, and hypoxia) and hemodynamic perturbations related to pain</population>
        <group_list>
          <group group_id="O1">
            <title>Exparel Inflitration</title>
            <description>Exparel infiltrated into the posterior compartment of the knee</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Saline infiltrated into posterior compartment</description>
          </group>
        </group_list>
        <measure>
          <title>Side Effects of Analgesia</title>
          <description>Secondary end points will include the incidence of opioid related side effects (nausea, vomiting, pruritis, constipation, respiratory depression, and hypoxia) and hemodynamic perturbations related to pain</description>
          <population>Number of patients with opioid related side effects (nausea, vomiting, pruritis, constipation, respiratory depression, and hypoxia) and hemodynamic perturbations related to pain</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>72 hours post-operative</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Exparel Inflitration</title>
          <description>Exparel infiltrated into the posterior compartment of the knee</description>
        </group>
        <group group_id="E2">
          <title>Control</title>
          <description>Saline infiltrated into posterior compartment</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Piyush M Gupta</name_or_title>
      <organization>Maimonides Medical Center</organization>
      <phone>7182837189</phone>
      <email>pgupta@maimonidesmed.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

